ECDC and EMCDDA technical guidance on prevention and control of infectious diseases among people who inject drugs
The content of this joint guidance was developed by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) with the support of a technical advisory group composed of policy makers, service providers, civil society representatives and preventative health experts from throughout the EU/EEA.
ECDC and EMCDDA technical guidance on prevention and control of infectious diseases among people who inject drugs - guidance in brief
This evidence-based guidance is designed to inform the development, monitoring and evaluation of national strategies and programmes in countries in Europe in order to reduce and prevent infections among people who inject drugs.
Risk assessment on change of testing requirements for partner donation of reproductive cells
In May 2011, the European Commission asked ECDC to estimate the change in total exposure risk to hepatitis B (HBV), hepatitis C (HCV) and human immunodeficiency virus (HIV) during reproductive cell handling and storage for secondary parties, if the current scheme of testing at each cell donation would change to testing partner donors of reproductive cells once or twice a year.
Public health guidance on HIV and STI prevention among men who have sex with men
This guidance, based on a systematic review of the literature and expert opinion, suggests that there is good evidence to ensure that some key components are considered for inclusion in national and sub-national public health programmes in countries in Europe.
Systematic review on hepatitis B and C prevalence in the EU/EEA
ECDC conducted a systematic review of the literature published between 2005–2015, with the aim to estimate the prevalence of hepatitis B and C in the general population and specific population subgroups in the EU/EEA Member States. This review is an update of an earlier review covering the period 2000–2009.
Effectiveness and cost-effectiveness of antenatal screening for HIV, hepatitis B, syphilis and rubella susceptibility
This literature review was conducted as part of a project evaluating the effectiveness of antenatal screening for HIV, hepatitis B, syphilis and rubella susceptibility in EU/EEA Member States.
Antenatal screening approaches effective in preventing MTCT of HIV, HBV, syphilis and rubella in vulnerable populations
In order to collect evidence on effective types of antenatal screening intervention that are effective for population groups vulnerable to MTCT, a review of the existing published literature was performed.
Public health guidance on antenatal screening for HIV, hepatitis B, syphilis and rubella susceptibility in the EU/EEA – addressing the vulnerable populations
This publication aims to support the strengthening of antenatal screening programmes for HIV, hepatitis B, syphilis and rubella susceptibility in the general population and in groups identified as vulnerable to mother-to-child-transmission in the EU/EEA.
Public health guidance on active case finding of communicable diseases in prison settings
This joint guidance from ECDC and the European Monitoring Centre for Drugs and Drug Addiction provides EU/EEA Member States with evidence-based scientific advice on active case finding options. These options can be applied to the planning and implementation of interventions that promote the early diagnosis of communicable diseases in prison settings.
ECDC and EMCDDA make the case for active case finding of communicable diseases in prison
In their joint public health Guidance published today, ECDC and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), present the evidence on active case finding as a key measure to diagnose communicable diseases early.